# Phase 2 glioma trials recruiting: 41 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 2 for glioma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 glioma trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/glioma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| September 21, 2026 | NCT07832123 | Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study | University of Zurich | Phase 2 | Not yet recruiting | Glioma : Oligodendroglioma or Astrocytoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832123) |
| September 15, 2026 | NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® | University of California, Irvine | Phase 2 | Not yet recruiting | Glioma, Glioblastoma, GBM, Glioma, Malignant, Astrocytoma, Oligodendroglioma, Elderly Glioblastoma, Elderly GBM | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821112) |
| August 10, 2026 | NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | Dongguan People's Hospital | Phase 2 | Not yet recruiting | Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754734) |
| July 16, 2026 | NCT07707973 | Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma | Tianjin First Central Hospital | Phase 2 | Not yet recruiting | Glioma, Malignant | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707973) |
| July 14, 2026 | NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive... | Nuvation Bio Inc. | Phase 2 | Recruiting | Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703436) |
| July 2, 2026 | NCT07680439 | Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). | BrainChild Bio, Inc | Phase 2 | Recruiting | Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680439) |
| July 1, 2026 | NCT07678684 | A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma | HighField Biopharmaceuticals Corporation | Phase 2 | Recruiting | Glioma, Adult | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678684) |
| June 12, 2026 | NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | Nationwide Children's Hospital | Phase 2 | Not yet recruiting | High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644312) |
| May 27, 2026 | NCT07609472 | FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma | FluoGuide A/S | Phase 2 | Not yet recruiting | High-Grade Glioma (WHO III-IV) | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609472) |
| May 15, 2026 | NCT07589257 | A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589257) |
| April 13, 2026 | NCT07521657 | Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Neurofibromatosis 1 (NF1) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521657) |
| March 10, 2026 | NCT07462507 | Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using \[C-11\]-CS1P1 | Washington University School of Medicine | Phase 2 | Recruiting | Central Nervous System Cancer, Brain Metastases | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462507) |
| February 27, 2026 | NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. | Cooper Norcross Health | Phase 2 | Recruiting | High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439172) |
| February 20, 2026 | NCT07424092 | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 | Recruiting | High Grade Glioma, Ependymoma, Embryonal Tumor of Brain, Recurrence, Refractory, Pediatric, Young Adult | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424092) |
| January 8, 2026 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Black Diamond Therapeutics, Inc. | Phase 2 | Recruiting | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System... | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326566) |
| October 3, 2025 | NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | Nationwide Children's Hospital | Phase 2 | Not yet recruiting | High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine... | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206849) |
| August 13, 2025 | NCT07120984 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or... | Philogen S.p.A. | Phase 2 | Not yet recruiting | Glioma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07120984) |
| February 21, 2025 | NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Nationwide Children's Hospital | Phase 2 | Recruiting | Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06838676) |
| February 10, 2025 | NCT06818331 | Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients... | The Third Affiliated hospital of Zhejiang Chinese Medical University | Phase 2 | Recruiting | Glioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06818331) |
| February 3, 2025 | NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors | University of Zurich | Phase 2 | Recruiting | Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma, Medulloblastoma, Meningioma, Rare Primary Brain... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06804655) |
| January 30, 2025 | NCT06801730 | Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Glioma | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06801730) |
| November 13, 2024 | NCT06687681 | Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas | Sponsor not shown (see the record) | Phase 2 | Recruiting | Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687681) |
| November 7, 2024 | NCT06678867 | The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours | University College, London | Phase 2 | Not yet recruiting | Brain Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06678867) |
| July 30, 2024 | NCT06528691 | Entrectinib as a Single Agent in Upfront Therapy for Children \<3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | St. Jude Children's Research Hospital | Phase 2 | Recruiting | High Grade Glioma, CNS Tumor | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06528691) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Nationwide Children's Hospital | 5 |
| University of Zurich | 2 |
| Northwell Health | 1 |
| German Cancer Research Center | 1 |
| University of Alabama at Birmingham | 1 |
| Centre Oscar Lambret | 1 |
| University of Vermont Medical Center | 1 |
| Washington University School of Medicine | 1 |
| Clinica Universidad de Navarra, Universidad de Navarra | 1 |
| HighField Biopharmaceuticals Corporation | 1 |
| Nuvation Bio Inc. | 1 |
| [Rigel Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/rigel-pharmaceuticals) | 1 |
| St. Jude Children's Research Hospital | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Cooper Norcross Health | 1 |
| The Third Affiliated hospital of Zhejiang Chinese Medical University | 1 |
| University of Milano Bicocca | 1 |
| Black Diamond Therapeutics, Inc. | 1 |
| University College, London | 1 |
| Guangzhou Virotech Pharmaceutical Co., Ltd. | 1 |
| University of Nebraska | 1 |
| Singapore General Hospital | 1 |
| University of California, San Francisco | 1 |
| Fore Biotherapeutics | 1 |
| BrainChild Bio, Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| Germany | 5 |
| Australia | 5 |
| Netherlands | 4 |
| China | 4 |
| Canada | 4 |
| New Zealand | 4 |
| United Kingdom | 4 |
| Switzerland | 3 |
| France | 2 |
| Spain | 2 |
| Italy | 2 |
| Brazil | 1 |
| Jordan | 1 |
| Peru | 1 |
| Singapore | 1 |
| Israel | 1 |
| Norway | 1 |
| South Korea | 1 |
| Sweden | 1 |
| India | 1 |
| Iran | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Credit and debt counseling services in the United States](https://specstream.ai/data/businesses/credit-and-debt-counseling-services/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Freight and cargo companies in the United States](https://specstream.ai/data/businesses/freight-and-cargo-companies/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
